22 June 2023  
EMA/286712/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Mircera 
methoxy polyethylene glycol-epoetin beta 
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Mircera. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted an extension to an existing indication for use in paediatric patients. For information, 
the full indications for Mircera will be as follows:2  
Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult 
patients (see section 5.1). 
Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in 
paediatric patients from 3 months to less than 18 years of age who are converting 
from another erythropoietin stimulating agent (ESA) after their haemoglobin level was 
stabilised with the previous ESA (see section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
